方法：选取2014-07/2016-01在本院接受治疗的老年湿性黄斑变性患者98例98眼作为研究对象。将患者按照入院顺序分为对照组和研究组，每组患者49例，对照组患者采用雷珠单抗进行治疗，研究组患者采用康柏西普进行治疗，两组患者均每月注射一次，连续注射3mo，对比两种药物治疗老年湿性黄斑变性的疗效。

结果：治疗前两组患者裸眼视力、黄斑中心凹视网膜厚度、CNV渗漏面积比较均无统计学意义(P>0.05)，治疗后1、3、6mo裸眼视力均较治疗前显著提高，黄斑中心凹视网膜厚度均较治疗前显著减小，CNV渗漏面积均较治疗前缩小，差异均具有统计学意义(P<0.05)。两组间比较，治疗后1mo裸眼视力、黄斑中心凹视网膜厚度、CNV渗漏面积比较均具有统计学意义(P<0.05)，治疗后3、6mo比较差异均无统计学意义(P>0.05)。随访期间两组患者均未见眼部严重并发症发生，如眼压持续升高、视网膜脱离、视网膜撕裂、眼内炎，均无全身严重不良反应的发生。治疗期间研究组发生球结膜下出血10眼，对照组8眼，均于治疗后 15d 内恢复，研究组发生暂时性眼压升高7眼，对照组9眼，两组并发症发生率比较无统计学意义(P>0.05)。

结论：在对老年湿性黄斑变性患者的临床治疗中，与雷珠单抗治疗方式相比，康柏西普治疗前期效果不明显，但是后期效果相当，并且更加经济实惠。

METHODS: We selected 98 patients 98 eyes with senile wet macular degeneration from July 2014 to January 2016 in our hospital as the research subjects. They were divided into control group and research group as the administration sequence, 49 patients in each group. Research group was treated with ranibizumab. The control group was treated with Conbercept. Both once per month and for 3mo.

RESULTS: Uncorrected visual acuity, central macular retinal thickness and area of choroidal neovascularization(CNV)leakage before treatment of the two groups were not statistically different(P>0.05). At 1, 3 and 6mo after treatment, the uncorrected visual acuity was improved significantly, the central macular retinal thickness decreased significantly, and the area of CNV leakage decreased significantly(P<0.05). The differences on uncorrected visual acuity at 1mo after treatment, central macular retinal thickness and area of CNV were statistically significant(P<0.05), while those indexes at 3 and 6mo after treatment was not significant(P>0.05). In the follow up period, there was no severe complications in the two groups, such as persistent high intraocular pressure, retinal detachment or tear, endophthalmitis, or other systemic complications. There were subconjunctival hemorrhage in 10 eyes in research group, 8 eyes in control group, all of which recovered within 15d after treatment. Transient elevated intraocular pressure occurred in 7 eyes in research group, in 9 eyes in control group. The complication rates of the two groups were not significant(P>0.05).

CONCLUSION: In the clinical treatment of senile patients with wet macular degeneration, treatment effect of Conbercept is not obvious at the early stage, but the effect is equivalent later and more economical.